TGTX Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . TG Therapeutics
TGTX Stock  USD 28.61  0.85  3.06%   
TG Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing TG Therapeutics' valuation are provided below:
Gross Profit
453.9 M
Profit Margin
0.8413
Market Capitalization
4.4 B
Enterprise Value Revenue
8.9213
Revenue
531.9 M
We have found one hundred twenty available fundamental measures for TG Therapeutics, which can be analyzed and compared to other ratios and to its peers in the sector. All investors should make sure to double-check all of TG Therapeutics latest market performance against the performance between 2010 and 2026 to make sure the company can sustain itself this quarter and beyond. Market Cap is likely to rise to about 2.3 B in 2026. Enterprise Value is likely to rise to about 2.3 B in 2026

TG Therapeutics Total Revenue

397.27 Million

Check TG Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among TG Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 338.1 K, Interest Expense of 29 M or Total Revenue of 397.3 M, as well as many indicators such as Price To Sales Ratio of 11.37, Dividend Yield of 4.0E-4 or PTB Ratio of 18.59. TGTX financial statements analysis is a perfect complement when working with TG Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with TGTX Stock
Check out the analysis of TG Therapeutics Correlation against competitors.
For more information on how to buy TGTX Stock please use our How to Invest in TG Therapeutics guide.

TG Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets697.6 M664.3 M244.4 M
Slightly volatile
Other Current Liabilities94.3 M89.8 M39.1 M
Slightly volatile
Total Current Liabilities109.5 M104.3 M44.6 M
Slightly volatile
Total Stockholder Equity268.5 M255.7 M125.7 M
Slightly volatile
Property Plant And Equipment Net8.6 M8.2 M5 M
Slightly volatile
Cash217.2 M206.9 M121.6 M
Slightly volatile
Non Current Assets Total7.6 M13 M11.9 M
Slightly volatile
Cash And Short Term Investments375.5 M357.6 M172.8 M
Slightly volatile
Common Stock Shares Outstanding193.6 M184.4 M86.2 M
Slightly volatile
Liabilities And Stockholders Equity697.6 M664.3 M244.4 M
Slightly volatile
Other Stockholder Equity2.1 B2 B870.6 M
Slightly volatile
Total Liabilities429.1 M408.6 M137.8 M
Slightly volatile
Property Plant And Equipment Gross8.6 M8.2 M5.1 M
Slightly volatile
Total Current Assets683.9 M651.3 M232.2 M
Slightly volatile
Other Current Assets19 M18.1 M8.4 M
Slightly volatile
Accounts Payable70.4 M67 M29 M
Slightly volatile
Common Stock Total Equity74.7 K131.4 K129.1 K
Pretty Stable
Common Stock107.8 K179.4 K134.8 K
Pretty Stable
Short and Long Term Debt Total306.4 M291.8 M71.6 M
Slightly volatile
Short Term Debt2.4 M1.3 M2.3 M
Pretty Stable
Other Liabilities260.8 K274.5 K2.3 M
Pretty Stable
Current Deferred Revenue13.8 M13.1 M5.2 M
Slightly volatile
Intangible Assets684 K720 K2.2 M
Slightly volatile
Net Tangible Assets118.5 M66.5 M94.3 M
Slightly volatile
Good Will865.8 K918.9 K790.2 K
Slightly volatile
Long Term Debt Total85.9 M81.8 M37.6 M
Slightly volatile
Capital Surpluse1.9 B1.8 B830.5 M
Slightly volatile
Short and Long Term Debt1.1 M1.1 M1.8 M
Pretty Stable
Net Invested Capital563.7 M536.8 M202.4 M
Slightly volatile
Net Working Capital574.4 M547 M199.6 M
Slightly volatile
Capital Stock146.1 K179.4 K113.4 K
Slightly volatile
Non Current Liabilities Other9.5 M9.3 M14.4 M
Slightly volatile
Capital Lease Obligations8.9 M8.4 M11.2 M
Slightly volatile

TG Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization338.1 K322 K207 K
Slightly volatile
Other Operating Expenses346.6 M330.1 M160.9 M
Slightly volatile
Research Development113.9 M108.4 M87.5 M
Slightly volatile
Total Operating Expenses300.2 M285.9 M152.4 M
Slightly volatile
Selling General Administrative186.3 M177.4 M91.3 M
Pretty Stable
Selling And Marketing Expenses11.5 M12.1 M73.7 M
Slightly volatile
Non Operating Income Net Other1.1 M2.1 M1.6 M
Very volatile
Interest Income6.4 M6.1 M2.8 M
Slightly volatile
Reconciled Depreciation319.9 K322 K208.5 K
Slightly volatile

TG Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow57.8 M108.4 M96.5 M
Slightly volatile
End Period Cash Flow218.8 M208.4 M122.3 M
Slightly volatile
Stock Based Compensation51.4 M48.9 M25.7 M
Slightly volatile
Change To Netincome23 M21.9 M19.6 M
Slightly volatile
Issuance Of Capital Stock39.6 M41.7 M123.5 M
Pretty Stable

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio11.3711.973.9 K
Very volatile
Dividend Yield4.0E-44.0E-46.0E-4
Slightly volatile
PTB Ratio18.5917.711.2162
Slightly volatile
Days Sales Outstanding124129139
Very volatile
Book Value Per Share1.671.76598
Slightly volatile
Average Payables6.3 M6 M5.2 M
Slightly volatile
Stock Based Compensation To Revenue0.140.1598.398
Slightly volatile
Capex To Depreciation0.140.16072.1193
Slightly volatile
PB Ratio18.5917.711.2162
Slightly volatile
Inventory Turnover0.330.310.1683
Slightly volatile
Days Of Inventory On Hand1.1 K1.2 K18.3 K
Slightly volatile
Payables Turnover0.00260.00280.0971
Slightly volatile
Sales General And Administrative To Revenue0.510.54126
Slightly volatile
Average Inventory3.3 M6.1 M5 M
Slightly volatile
Research And Ddevelopement To Revenue0.250.26412
Slightly volatile
Capex To Revenue1.0E-41.0E-40.3994
Very volatile
Cash Per Share2.342.46656
Slightly volatile
Days Payables Outstanding142.6 K135.8 K116.5 K
Slightly volatile
Intangibles To Total Assets0.00260.00280.0597
Slightly volatile
Net Debt To EBITDA1.331.71.1669
Pretty Stable
Current Ratio5.797.186.1301
Slightly volatile
Receivables Turnover2.782.933.7411
Slightly volatile
Graham Number1.542.121.5948
Slightly volatile
Shareholders Equity Per Share1.671.76598
Slightly volatile
Capex Per Share3.0E-44.0E-428.4183
Slightly volatile
Average Receivables127.6 K155.2 K122.7 K
Pretty Stable
Revenue Per Share2.472.628.9512
Slightly volatile
Interest Debt Per Share2.092.211.3046
Slightly volatile
Debt To Assets0.780.510.3932
Pretty Stable
Operating Cycle1 K1.1 K6.8 K
Very volatile
Price Book Value Ratio18.5917.711.2162
Slightly volatile
Days Of Payables Outstanding142.6 K135.8 K116.5 K
Slightly volatile
Ebt Per Ebit1.060.70.9336
Slightly volatile
Company Equity Multiplier2.462.341.9917
Slightly volatile
Total Debt To Capitalization0.320.610.3249
Very volatile
Quick Ratio5.715.785.9263
Slightly volatile
Net Income Per E B T1.01.050.9596
Slightly volatile
Cash Ratio2.172.284.152
Slightly volatile
Days Of Inventory Outstanding1.1 K1.2 K18.3 K
Slightly volatile
Days Of Sales Outstanding124129139
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.121.151.0182
Slightly volatile
Price To Book Ratio18.5917.711.2162
Slightly volatile
Fixed Asset Turnover43.4841.4113.6131
Slightly volatile
Debt Ratio0.780.510.3932
Pretty Stable
Price Sales Ratio11.3711.973.9 K
Very volatile
Asset Turnover0.410.650.1428
Slightly volatile
Gross Profit Margin0.50.790.7136
Pretty Stable
Price Fair Value18.5917.711.2162
Slightly volatile

TG Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.3 B2.2 B1.3 B
Slightly volatile

TGTX Fundamental Market Drivers

Forward Price Earnings22.7273
Cash And Short Term Investments311 M

TGTX Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
6th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About TG Therapeutics Financial Statements

TG Therapeutics investors use historical fundamental indicators, such as TG Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in TG Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue13.1 M13.8 M
Total Revenue378.4 M397.3 M
Cost Of Revenue44.3 M23.1 M
Stock Based Compensation To Revenue 0.15  0.14 
Sales General And Administrative To Revenue 0.54  0.51 
Research And Ddevelopement To Revenue 0.26  0.25 
Revenue Per Share 2.60  2.47 
Ebit Per Revenue 0.13  0.15 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill

Additional Tools for TGTX Stock Analysis

When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY